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Key Points
• Over the last decade, allogeneic
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administered in the United States
to adults aged 70 and older with
hematologic malignancies.
• Allogeneic transplant outcomes
were reasonable; high comorbidity
and ablative conditioning regimens
were associated with inferior
outcomes.
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In this study, we evaluated trends and outcomes of allogeneic hematopoietic cell transplantation (HCT) in adults ‡70 years with
hematologicmalignancies across theUnitedStates.Adults‡70yearswith ahematologicmalignancyundergoing first allogeneicHCT
in the United States between 2000 and 2013 and reported to the Center for International Blood andMarrow Transplant Researchwere
eligible. Transplant utilization and transplant outcomes, including overall survival (OS), progression-free survival (PFS), and
transplant-related mortality (TRM) were studied. One thousand one hundred and six patients ‡70 years underwent HCT across 103
transplant centers. The number and proportion of allografts performed in this population rose markedly over the past decade,
accounting for 0.1% of transplants in 2000 to 3.85% (N 5 298) in 2013. Acute myeloid leukemia and myelodysplastic syndromes
represented themost commondisease indications. Two-yearOSandPFSsignificantly improvedover time (OS: 26% [95%confidence
interval (CI), 21% to 33%] in 2000-2007 to 39% [95%CI, 35% to 42%] in 2008-2013,P < .001; PFS: 22% [16% to 28%] in 2000-2007 to 32%
[95% CI, 29% to 36%] in 2008-2013, P 5 .003). Two-year TRM ranged from 33% to 35% and was unchanged over time (P 5 .54).
Multivariable analysis of OS in the modern era of 2008-2013 revealed higher comorbidity by HCT comorbidity index ‡3 (hazard ratio
[HR], 1.27;P5 .006), umbilical cord blood graft (HR, 1.97;P5 .0002), andmyeloablative conditioning (HR, 1.61;P5 .0002) as adverse
factors. Over the past decade, utilization and survival after allogeneic transplant have increased in patients ‡70 years. Select adults
‡70 years with hematologic malignancies should be considered for transplant. (Blood. 2017;130(9):1156-1164)
Introduction
Allogeneic hematopoietic cell transplantation (HCT) offers the best
potential for prolonged disease control for many hematologic malig-
nancies. Historically, older adults were not considered candidates out of
concern for increased toxicity and mortality,1 thus excluding the
majority of hematologic malignancy patients who may have gained
benefit. In recent years, the development of reduced-intensity
conditioning (RIC) and nonmyeloablative (NMA) regimens,2 coupled
with improvements in supportive care measures3 and more accurate
HLA typingmethods,4 has broadened the application ofHCT to include
older adults. As such, 22% of HCT recipients for malignant diseases
from 2007 to 2013 reported to the Center for International Blood and
Marrow Transplant Research (CIBMTR) were.60 years of age.5
The feasibility of HCT in adults.50 years of age, and even those
.65 years, has been detailed in several reports.6-11 In a registry analysis
of patients with acute myeloid leukemia (AML) in first remission or
myelodysplastic syndrome (MDS) receiving RIC allogeneic trans-
plants, no significant differences in outcomes were uncovered among
HCT recipients aged 40 to 50 years versus those .65 years.7 Similar
results have been reported in multicenter series from the United States
and the European Society for Blood and Marrow Transplantation,
where disease status and medical comorbidities, rather than chrono-
logical age, appear to predict for outcomes.6,8,11
Although most studies conclude that older age alone should not
preclude transplant, very limited data exist regarding patients trans-
planted in their eighth decade.12 This population is of particular interest,
as it has been shown that for each 5-year increase in age beyond
65 years, the proportion of cancer patients with comorbidity, disability,
and/or geriatric syndromes increases by 3% to 5%,13,14 prompting
recommendations to perform a comprehensive geriatric assessment for
all cancer patients in this age group.15 Further, as the population
continues to age, with 50% of all cancers and 70% of cancer mortality
occurring in adults $65 years, the number of patients considered for
HCT in their eighth decade will continue to rise.16
We therefore conducted an observational study of allogeneic HCT
recipients$70 years reported to the CIBMTR between 2000 and 2013
with the aims of describing transplant utilization as well as baseline
characteristics, outcomes, and prognostic factors for this understudied
cohort of HCT recipients.
Methods
Data sources
The CIBMTR is a research collaboration between the National Marrow Donor
Program/Be The Match and the Medical College of Wisconsin. The CIBMTR
represents an international network of transplant centers that submit transplant-
related data for patients. It has been collectingHCToutcomes data for.40 years
andhas an extensive database of detailedpatient-, transplant-, anddisease-related
information with prospectively collected longitudinal data.17 CIBMTR data are
collected in compliance with Health Insurance Portability and Accountability
Act regulations and with all applicable federal regulations pertaining to the
protection of human research participants, as determined by a continuous review
by the National Marrow Donor Program institutional review board and the
Medical College of Wisconsin.
The CIBMTR collects 2 levels of data: registration-level data are retrieved
from Transplant Essential Data forms, and additional research level data are
collectedusingComprehensiveReport Forms (CRFs).The latter is a subset of the
former; patients for whom CRF-level data are collected are chosen through a
selection algorithm, as these forms are longer and require more extensive data,
including detailed disease information. Thus, the objective of this study included
assessing transplant practices and activity in the United States using Transplant
Essential Data–level data. Additional analysis with more detailed disease-
specific information was performed in a subset of this population as described in
statistical section below.
Patient population
Patients aged$70 years at time of first allogeneic HCT occurring between 2000
and 2013 and reported to the CIBMTR were included. Exclusion criteria
included syngeneic donor transplant and patients reported to the CIBMTR who
received HCT outside of the United States.
Definitions and outcomes
Disease status at time of transplant followedCIBMTRdisease risk classification18:
early disease (acute leukemia in first complete remission, myelodysplastic syn-
dromes with ,5% blasts, or chronic-phase chronic myeloid leukemia [CML]),
intermediate disease (second or greater complete remission acute leukemia,
accelerated-phase CML), and advanced disease (acute leukemia not in remis-
sion, myelodysplastic syndromes with$5%marrow blasts, or blast-phase CML);
lymphomas were classified according to chemotherapy sensitivity (sensitive or
resistant at time of transplant). Patients with AML were also described in greater
detail using CRF data to report disease characteristics of interest, including
frequency of favorable, intermediate, and poor cytogenetic categories and pres-
ence or absence of FLT3 mutations. Conditioning regimen intensity followed
CIBMTR working definitions (myeloablative vs RIC/NMA)19,20; due to data
capture constraints, RIC and NMA were grouped together. Comorbidity was
scored using the HCT comorbidity index; recipient HCT-comorbidity index
scores have been routinely reported to the CIBMTR on all allogeneic HCT
recipients since 2008. Performance status was captured by the Karnofsky
Performance Scale (KPS). Disease Risk Index (DRI)21 was evaluated in the
entire population and categorized in a subset of patients with all available
elements. HLA-matched unrelated donors required 8/8 matching at HLA-A,
HLA-B,HLA-C,andHLA-DRB1athigh resolution.Mismatched relateddonors
included haploidentical donors as well as single-antigen and allele mismatches
BLOOD, 31 AUGUST 2017 x VOLUME 130, NUMBER 9 ALLOGENEIC HCT IN ADULTS 70 YEARS AND OLDER 1157
For personal use only.on April 12, 2019. by guest  www.bloodjournal.orgFrom 
(ie, 7 of 8). Neutrophil engraftment was defined as neutrophil count above
500/mL for 3 consecutive days. Graft-versus-host disease (GVHD) was defined
as acute GHVD (grades II-IV or III-IV according to maximum organ
stage) or chronic GVHD.
The primary outcome for this study was overall survival (OS), defined as
death from any cause; patients for whom death was not observed were censored
at the time of last follow-up. Transplant-related mortality (TRM) was defined as
death in the absenceofdisease relapseorprogression.The composite endpoint of
progression-free survival (PFS) required either disease relapse or progression or
death; patients alive without such events were censored at the time of last follow
up. Primary cause of death for each patient was reported by the treating center.
Statistical analysis
Descriptive statistics summarized the baseline patient, disease, and transplant-
related characteristics according to two time cohorts during the study period
(2000 to2007, 2008 to2013).Theproportionof transplants performed inpatients
70 years of age and older relative to all transplants performed in theUnited States
was computed. Univariate summary measures for all outcomes were calculated
and compared over the two time periods. Probabilities of OS and PFS were
calculated using the Kaplan-Meier estimator, and comparisons between groups
were performed using log-rank and point-wise tests. Probabilities of neutrophil
engraftment, GVHD, TRM, and disease relapse/progression were calculated by
cumulative incidence function accounting for competing risks. Comparisons of
cumulative incidence across time cohorts were performed via Gray’s test.
Prognostic factor analysis was performed on 3 patient subsets. The first
analysis included all patients $70 years transplanted between 2008 and 2013
with the intention of focusing on a contemporary cohort of patients with all
disease indications who received comorbidity assessment by the HCT-
comorbidity index (which was not available prior to 2008). For this subset, a
multivariable Cox proportional hazards regression model was built using
stepwise variable selection to evaluate patient, disease, and transplant variables
associated with OS. The variables analyzed were age (70-74 and $75 years),
gender, HCT-comorbidity index (0-2 and $3),22 KPS (modeled at $80% and
$80%), disease, disease status, donor type (HLA-matched sibling, HLA-
mismatched related, and HLA matched unrelated donor, divided according to
donor age [,30 and$30 years] ormismatched unrelated donor, unrelated donor
withHLA-matching unknown, and umbilical cord blood), conditioning regimen
intensity19,20 graft source (bone marrow, mobilized peripheral blood stem cells,
and umbilical cord blood), year of transplant, donor-recipient gender match,
donor–recipient cytomegalovirus serologic status, and GVHD prophylaxis
(calcineurin inhibitor andmethotrexate, calcineurin inhibitor andmycophenolate
mofetil, and calcineurin inhibitor with other combinations and other regimens).
The second subset analysis explored variables associated with OS and TRM
among patients $70 years with controlled disease entering transplant. This
subset included patients with early or intermediate-risk AML (ie, patients
in complete remission 1 [CR1] or CR2 as opposed to active disease), MDS
with ,5% blasts, and chemosensitive non-Hodgkin lymphoma (NHL) who
underwent HCT between 2008 and 2013. This more homogenous subset
included the most common disease indications for HCT among older adults and
enabled analysis of variables associated with TRM without confounding from
less common transplant disease indications. Multivariable Cox regression
models were constructed by testing the covariates as abovewith the exception of
disease status as all patients in this subset had early or intermediate disease at
transplant.
The third subset focused on exploring outcomes by comorbidity and disease
status in patients with AML andMDS undergoing transplant between 2008 and
2013. For this subset, probabilities of OS and TRM were calculated as above.
For multivariable analysis performed in the first and second subsets, all
covariates associated with outcome at P, .05 were retained in the final models
and considered significant. Tests of proportionality for each covariate and of
interaction between covariates were performed; no violations of proportionality
or significant interactions were found. All analyses were performed using
SAS 9.2 (SAS Institute, Cary, NC).
Results
HCT utilization for adults 70 years and older over time
A total of 1106 patients$70 years underwent first allogeneic HCT in
the United States andwere reported to the CIBMTR between 2000 and
2013. The absolute number of transplants for adults $70 years
increased substantially over that time, from 5 in 2000 to 283 in 2013.
The proportion of allogeneic HCT recipients$70 years also increased
over time, from 0.1% in 2000 to 3.85% in 2013. Further, the absolute
number of transplant programs performing allogeneic HCT in patients
$70 years increased from 65 centers in 2000-2007 to 93 centers in
2008-2013. Transplant for AML and MDS accounted for the main
indications across time periods (Figure 1).
Patient and HCT characteristics
Baseline patient demographics and transplant characteristics stratified
by HCT time period for all patients in the dataset are described in
Table 1. The median age at time of HCT was 72 (range, 70-84 years).
KPS was ,80% in 9% of the patients. Comorbidity by HCT-
comorbidity index (captured for recipients transplanted from 2008 to
2013) demonstrated high HCT-comorbidity index of $3 in 46% of
patients; 16% had HCT-comorbidity index scores of $5. Among
patients with available DRI, the majority received transplant with
intermediate risk. The donor source shifted from related donors in 51%
in the initial time period to 70%unrelated grafts in the later time period,
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Figure 1. Annual number of HCTs in patients 70 years
and older by indication. MPS, myeloproliferative syndrome.
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driven mostly be greater use of matched unrelated donors over time.
Although most patients received RIC/NMA conditioning regimens,
myeloablative regimens were administered to 10% overall. The more
widespread use of fludarabine plus busulfan–based regimens signified
the largest change in conditioning regimens over time. Increasing
numbers of patients entered transplant with controlled disease in the
more recent time period.
Supplemental Table A (available on the Blood Web site) includes
additional disease and transplant-related details regardingAMLpatients
transplanted between 2008 and 2013. In this subset of 120 patients with
AML with available information, 70% had intermediate cytogenetics,
85% of patients with available FLT3 status were wild-type, and 69%
were in morphologic complete remission at time of transplant.
Outcomes
Unadjusted 1- and 2-year transplant outcome probabilities (neutrophil
engraftment, grades II-IV and III-IV acute GVHD, chronic GVHD,
TRM, relapse/progression, PFS, andOS) stratified byHCT time period
are summarized in Table 2. Two-year PFS improved significantly from
2000-2007 to 2008-2013 (22% [95% confidence interval (CI) 16% to
28%] vs 32% [29% to 36%], P 5 .003), while TRM remained static
(P 5 .54 over the entire time period). Two-year OS also improved
significantly over time, from 26% [95% CI, 21% to 33%] in
2000-2007% to 39% [95% CI, 35% to 42%] in 2008-2013, P , .001
(Figure 2A). Overall and disease-free survival among patients with
the most common indications for HCT from 2008 to 2013 and
according to DRI in the same period are shown in Figure 2B-E).
Table 1. Demographics of patients 70 years and older who received
HCT from 2000 to 2013
2000-2007,
n (%)
2008-2013,
n (%)
All patients,
n (%)
No. of patients 207 899 1106
No. of centers 65 93 103
Age at transplant, y
Median (range) 72 (70-83) 72 (70-84) 72 (70-84)
70-74 176 (85) 807 (90) 983 (89)
75-79 27 (13) 88 (10) 115 (10)
$80 4 (2) 4 (,1) 8 (1)
Sex
Male 151 (73) 629 (70) 780 (71)
Female 56 (27) 270 (30) 326 (29)
KPS
,80% 17 (8) 87 (10) 104 (9)
$80% 119 (57) 784 (87) 903 (82)
Missing 71 (34) 28 (3) 99 (9)
HCT-comorbidity index
0 — 248 (28) 248 (22)
1-2 — 234 (26) 234 (21)
$3 — 417 (46) 417 (38)
Missing* 207 0 207 (19)
Disease
AML 103 (50) 496 (55) 599 (54)
ALL 2 (,1) 23 (3) 25 (2)
CLL/PLL 22 (11) 54 (6) 76 (7)
CML 5 (2) 6 (,1) 11 (,1)
MDS/MPS 32 (15) 215 (24) 247 (22)
Other acute leukemia 1 (,1) 8 (,1) 9 (,1)
NHL 23 (11) 90 (10) 113 (10)
Plasma cell disorder/multiple myeloma 10 (5) 2 (,1) 12 (1)
Other malignancies 3 (1) 0 3 (,1)
Severe aplastic anemia 4 (2) 5 (,1) 9 (,1)
PNH 2 (1) 0 2 (,1)
Disease status
Early disease 45 (22) 355 (39) 300 (27)
Intermediate disease 25 (12) 93 (10) 118 (11)
Advanced disease 48 (23) 230 (26) 278 (25)
NHL sensitive 10 (5) 79 (10) 89 (9)
NHL resistant 6 (3) 10 (1) 16 (1)
Other (unknown/missing/NA) 73 (35) 132 (15) 205 (19)
DRI†
Low 6 (3) 32 (4) 38 (3)
Intermediate 28 (14) 152 (17) 180 (16)
High 20 (10) 115 (13) 135 (12)
Very high 7 (3) 18 (2) 25 (2)
Other (missing/NA) 146 (71) 582 (65) 728 (66)
Donor type
Matched related 93 (45) 204 (23) 297 (27)
Mismatched related 13 (6) 67 (7) 80 (7)
Matched unrelated 52 (25) 463 (52) 515 (47)
Mismatched unrelated 12 (6) 68 (8) 80 (7)
Unrelated HLA match unknown 20 (10) 46 (5) 66 (6)
Umbilical cord blood 7 (3) 51 (6) 58 (5)
Missing 10 (5) 0 10 (1)
Unrelated donor age, median
(range), y
36 (21-60) 30 (19-61) 31 (19-61)
18-30 23 (27) 278 (48) 301 (46)
31-40 24 (29) 139 (24) 163 (25)
41-50 21 (25) 96 (17) 117 (18)
51-61 5 (6) 25 (4) 30 (5)
Unknown 11 (13) 39 (7) 50 (8)
Graft source
Bone marrow 17 (8) 93 (10) 110 (10)
Peripheral blood 183 (88) 755 (84) 938 (85)
Umbilical cord blood 7 (3) 51 (6) 58 (5)
Table 1. (continued)
2000-2007,
n (%)
2008-2013,
n (%)
All patients,
n (%)
Donor–recipient sex match
Male–male 95 (46) 388 (43) 483 (44)
Male–female 25 (12) 154 (17) 179 (16)
Female–male 50 (24) 203 (23) 253 (23)
Female–female 30 (14) 98 (11) 128 (12)
Unknown 7 (3) 56 (6) 63 (6)
Donor–recipient CMV status
Positive–positive 16 (8) 269 (30) 285 (26)
Positive–negative 7 (3) 67 (7) 74 (7)
Negative–positive 37 (18) 292 (32) 329 (30)
Negative–negative 13 (6) 176 (20) 189 (17)
Unknown 134 (65) 95 (11) 229 (21)
Regimen intensity
Ablative 11 (5) 102 (11) 113 (10)
RIC/NMA 178 (86) 796 (89) 974 (88)
Unknown 18 (9) 1 (,1) 19 (2)
Conditioning regimen
Flu/Bu 6 other 29 (14) 368 (41) 397 (36)
Flu/Mel 6 other 35 (17) 137 (15) 172 (16)
Flu/TBI 6 other 65 (31) 274 (30) 339 (31)
Bu based 11 (5) 17 (2) 28 (3)
Flu/Cy 6 other 26 (13) 40 (4) 66 (6)
TBI/TLI 6 other 16 (8) 49 (5) 65 (6)
Other 17 (8) 14 (2) 31 (3)
Unknown 8 (4) 0 8 (,1)
ALL, acute lymphoblastic leukemia; Bu, busulfan; CLL, chronic lymphocytic
leukemia; CMV, cytomegalovirus; Flu/Bu, fludarabine 1 busulfan; Flu/Mel, fludar-
abine 1 melphalan; Flu/TBI, fludarabine 1 total body irradiation; MPS, myelo-
proliferative syndrome; NA, not available; PLL, prolymphocytic leukemia; PNH,
paroxysmal nocturnal hemoglobinuria; Flu/Cy, fludarabine 1 cyclophosphamide;
TBI/TLI, total body irradiation or total lymphoid irradiation.
*HCT-comorbidity index was not captured by the CIBMTR registry prior to 2008.
†All elements required to generate the DRI were not available in all patients.
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The most frequent primary cause of death was relapse/progression
of primary disease, which accounted for 46% of deaths. Infection and
GVHDwere each reported as the primary cause of death in 10%.Cause
of death could not be clarified in 22% of the patients.
Prognostic factor analysis in modern cohorts
The first subset analysis focused on all patients $70 years transplanted
between2008and2013.Significantprognostic factors for inferior survival
included high comorbidity defined by HCT-comorbidity index $3
(hazard ratio [HR], 1.27; 95% CI, 1.07-1.51; P5 .006), receipt of cord
bloodas adonor source (HR,1.97; 95%CI, 1.37-2.82;P5 .0002) relative
to HLA matched sibling donor, and use of a myeloablative conditioning
regimen (HR, 1.61; 95% CI, 1.25-2.08; P5 .0002) (Table 3). All other
variables tested in the model, including age, disease status, disease, and
KPS, were not found to significantly influence survival.
Table 3 highlights variables significantly associated with TRM and
OS among the subset of 416 HCT recipients with early or intermediate
AML orMDS or chemosensitive NHL transplanted between 2008 and
2013. Female relative tomale recipients (HR, 1.30; 95%CI, 1.03-1.65;
P 5 .029) and myeloablative conditioning as opposed to RIC/NMA
(HR, 1.60; 95% CI, 1.13-2.28; P5 .009) were associated with higher
mortality. Conditioning regimen intensity was the only signifi-
cant covariate associated with TRM (HR, 2.06; 95% CI, 1.32-3.22;
P 5 .001) in this subset.
Supplemental Figure 1A-D demonstrates OS and TRM, respec-
tively, for patients with AML or MDS who underwent transplantation
between 2008 and 2013 based upon both disease risk at time of
transplantation (early/intermediate disease vs advanced disease) and
also by comorbidity score (ie, HCT ,3 vs $3). High comorbidity in
this population appeared to have a greater adverse impact on patients
with advanced or active disease at time of transplant as opposed to
patients with early or intermediate disease (ie, in remission) at the time
of transplant.
Discussion
In the current observational study, we report on the utilization,
characterization and prognostic factors associatedwith allogeneicHCT
in adults$70 years. Our findings, derived from a large national cohort
of patients transplanted in the United States over the last decade,
demonstrate that the absolute number and proportion of allogeneic
transplants performed for adults in their eighth decade has risen steadily
on ayearly basis since2000, such that patients$70years now represent
nearly 4% of allogeneic HCT recipients.
Several factors spurred the increase in transplant volume for this
population. The majority of growth was in fact due to increasing
numbers of patients with early or intermediate-risk AML or MDS as
defined by the CIBMTR (ie, AML in CR1 or greater; MDS with
,5% blasts) transplanted since 2008. Greater utilization of HCT for
MDS beginning after 2010 coincides with the decision in the United
States to cover this disease indication for Medicare beneficiaries
Table 2. Univariate analysis of posttransplant outcomes of patients aged 70 years and older and recipients of an allogeneic HCT from
2000 to 2013
Total cohort 2000-2007 2008-2013
P*prob. (95% CI) prob. (95% CI) prob. (95% CI)
Neutrophil engraftment†
No. evaluated — — 890 —
28 d — — 92 (90-93) —
Acute GVHD, grade II-IV
No. evaluated 427 105 322 .63
100 d 32 (28-37) 31 (23-41) 33 (28-38) .82
Acute GVHD, grade III-IV
No. Evaluated 427 105 322 .05
100 d 13 (10-17) 18 (11-26) 12 (9-16) .13
Chronic GVHD
No. evaluated 1025 161 864 .94
1 y 32 (30-35) 32 (25-40) 32 (29-36) .97
2 y 37 (34-40) 35 (28-43) 38 (35-41) .55
TRM
No. evaluated 1086 192 894 .77
1 y 25 (23-28) 26 (20-33) 25 (22-28) .73
2 y 33 (30-36) 35 (28-42) 33 (29-36) .54
Relapse/progression
No. evaluated 1086 192 894 .04
1 y 32 (30-35) 38 (31-45) 31 (28-34) .09
2 y 37 (34-40) 43 (36-50) 35 (32-38) .04
PFS
No. evaluated 1086 192 894 .001
1 y 42 (39-45) 36 (29-43) 44 (40-47) .04
2 y 30 (27-33) 22 (16-28) 32 (29-36) .003
OS
No. evaluated 1106 207 899 ,.001
1 y 50 (47-53) 42 (35-49) 52 (49-56) .007
2 y 36 (33-39) 26 (21-33) 39 (35-42) ,.001
Prob., probability.
*P value for significance between the 2000-2007 and 2008-2013 cohorts.
†Neutrophil engraftment was not consistently captured prior to 2008.
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participating in an approved clinical study through the Center for
Medicare and Medicaid Services Coverage with Evidence Devel-
opment.23 Additionally, the increasing use of unrelated donors (and,
to some extent, haploidentical or cord blood donor stem cell sources)
relative to sibling donors fueled transplant growth by substantially
expanding donor availability. Perhaps themost important yet difficult to
measure factor is the societal changes that have prompted physician and
patient willingness to consider transplant. Similar trends in uptake for
older patients have been reported in autologous transplants where donor
sources are irrelevant, as well as in solid organ transplantation.24,25
Despite increased utilization of HCT for this older adult popula-
tion, the relatively small number of allogeneic transplants confirms
reports by others26,27 that the vast majority of adults aged $70 years
with transplant-eligible hematologic malignancies are not undergoing
HCT. For example, according to the National Cancer Institute’s
Surveillance, Epidemiology, and End Results Program, there are
;3000 new cases of AML diagnosed per year in adults aged 70 to 79
years in the United States (http://seer.cancer.gov/). Our data reveal that
only 253 AML patients aged $70 years underwent allogeneic HCT
between 2012 and 2013, representing only 4% of the population of
newlydiagnosedAMLpatients in their eighthdecadeof life.Transplant
was even more rarely pursued in this age group for other disease
indications, such as NHL (n5 113) and acute lymphoblastic leukemia
(n5 25).
The lack of transplant outcome data in this age group has been
a major impediment and previously has been restricted to reports
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Figure 2. Allogeneic HCT outcomes in adults 70 years and older. (A) OS after HCT in patients $70 years by year of transplant (2000-2007 vs 2008-2013). (B) Disease-
free survival after HCT in patients $70 years with AML in remission, myelodysplasia, and chemotherapy-sensitive NHL from 2008 to 2013. (C) OS after HCT in patients $70
years with AML in remission, myelodysplasia, and chemotherapy-sensitive NHL from 2008 to 2013. (D) Disease-free survival after HCT in patients $70 years from 2008 to
2013 according to DRI. (E) OS after HCT in patients $70 years from 2008 to 2013 according to DRI.
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including small numbers of these patients.11,27We found that transplant
survival has significantly improved over time for this older adult
population, with 2-year PFS andOS estimates of 32% (95%CI, 29% to
36%) and 39%(95%CI, 35% to 42%), respectively, forHCT recipients
transplanted in the more recent era of 2008-2013. As TRM and severe
acute GVHD did not change over time, improvements were likely
mediated in part by transplant in patients with less advanced disease.
Consistent with this, a greater proportion of patients entered transplant
with earlier-risk disease (recognizing many were missing disease risk
in earlier years), and improvements occurred in PFS and cumulative
incidence of disease relapse.
Given the methodological issues and biases associated with ret-
rospectively comparing treatment approaches, prospective studies are
required toeffectively evaluateHCTversus non-HCT therapies in older
adults for each disease indication. Few studies report outcomes of
patients $70 years after nontransplant treatment to benchmark these
results, and lack of consistent patient health information reported in
these studies hinders identification of transplant-eligible subsets. In
a population study of AML from the Netherlands, 69% of patients
$70 years received some form of chemotherapy, but no patients were
allografted, resulting in dismal 1- and 5-year survival rates of 15% and
2%, respectively, for patients diagnosed between 2007 and 2012.28
Thus, our study outcomes forAMLpatients transplanted between 2008
and 2013, revealing 2-year PFS and OS of 36% and 38%, respectively,
appear extremely encouraging and suggest that select older patients
achieve a substantial disease and survival benefit after HCT.
Concerns regarding treatment-related morbidity and mortality
likely account for reluctance to offer transplant to older patients. Our
findings that TRM has remained stable over the decade, with 2-year
estimates at 30% to 35%, is similar to the findings of the registry
analysis, where 2-year TRM ranged from 25% to 39% in adults
$40 years with AML and MDS following RIC HCT, without signif-
icant differences across age groups.7 Registry summaries inclusive of
heterogeneous disease status, donor type, and conditioning regimen
may be less favorable than institutional protocol reports of more
selected patients yet reflect present population-based practice patterns
and results. Although supportive care for hematologic malignancy and
transplant recipients has improved considerably in recent years, so
much so as to allow the application of allogeneic HCT to patients
$70 years, appreciable TRM remains a barrier to transplant utilization
and success in this group. Impairments in adaptive immune response
with aging are accentuated in the allogeneic transplant setting and likely
contribute to the relatively high rates of transplant-related morbidity
and mortality in older patients.29 Strategies to overcome thymic
impairments with aging and allogeneic transplant are of considerable
interest.30 Higher rates of TRM in those patients 70 years and older
with advanced disease and high comorbidity suggest that transplant
should be pursued with particularly caution in such patients.
To reduce TRM, we must consider improvements in patient
selection and further refine the transplant process to allow for less
toxicity andmorbidity in older adults. Similar to others,11we found that
inferior survival was associatedwith high comorbidity, albeit with only
a modest effect (HR, 1.27; 95%CI, 1.07-1.51). Patients$75 years did
not fare significantly worse than those 70 to 74 years of age. Therefore,
age alone or moderate degrees of comorbidity are insufficient to
determine transplant eligibility. Enhanced discrimination may be
obtained with the use of geriatric assessment prior to HCT.31
Geriatric assessment for evaluation and guided interventions warrant
additional research to abrogate morbidity and mortality.15,32 More
precise risk stratification for TRM, if not survival, may paradoxically
Table 3. Multivariate models for overall mortality (1 2 OS) and TRM in patients aged 70 years and older who received an allogeneic HCT
Effect No. HR 95% CI P
Overall mortality
HCT-comorbidity index
0-2 479 1.000 — —
$3 415 1.269 1.070, 1.504 .0061
Donor type .0046*
HLA-matched, related 202 1.000 — —
HLA-mismatched, related 67 1.209 0.848, 1.724 .2932
HLA-matched, URD , 5 30 y old 233 0.933 0.726, 1.199 .5874
HLA-matched, URD . 30 y old 210 1.144 0.898, 1.457 .2754
HLA-matched, URD of unknown age 19 0.838 0.425, 1.649 .6080
HLA-mismatched, URD 67 1.324 0.945, 1.854 .1025
HLA matching unknown, URD 45 1.178 0.782, 1.775 .4340
UCB 51 1.963 1.372, 2.809 .0002
Conditioning intensity
RIC/NMA 791 1.000 — —
Overall mortality for patients with early/intermediate AML/MDS and chemosensitive NHL
Sex
Male 359 1.00 — —
Female 165 1.30 1.03-1.65 .03
Conditioning intensity
RIC/NMA 473 1.00 —
MA 50 1.60 1.13-2.28 .009
TRM for patients with early/intermediate AML/MDS and chemosensitive NHL
Conditioning intensity
RIC/NMA 473 1.00 — —
MA 50 2.06 1.32-3.22 .001
The first model for overall mortality in a population from 2008 to 2013 and all hematologic malignances. The second multivariate analysis includes models for overall
mortality for patients with early/intermediate AML/MDS and chemosensitive NHL and TRM for a subset of patients with early and intermediate AML and MDS who received an
allogenic HCT from 2008 to 2013.
MA, myeloablative; UCB, umbilical cord blood; URD, unrelated donor.
*Donor type variable was tested with 7 degrees of freedom and divided the group of matched unrelated donor according to donor age divided at the median.
1162 MUFFLY et al BLOOD, 31 AUGUST 2017 x VOLUME 130, NUMBER 9
For personal use only.on April 12, 2019. by guest  www.bloodjournal.orgFrom 
expand the number of older patients eligible for transplant by
delineating a larger pool of patients with acceptable transplant risks.
Similar to younger patients, disease relapse remains the primary
cause of death in older transplant recipients. However, more
intensive transplant conditioning via myeloablative regimens was
associated with worse OS in the whole cohort and in the subset of
early/intermediate AML/MDS and chemosensitive NHL. While
new disease scoring systems such as the DRI- and minimal residual
disease–based assessments have been used to evaluate relapse risk
in younger HCT patients, the importance of these tools in older
patients is less established.21,33 For example, independent of the
DRI, older patients fare worse, and minimal residual disease
measures have a less pronounced effect on relapse after NMA
transplant for AML and have not been shown to affect survival in
this population.33 This likely reflects the adverse biology of disease
in older age in that even after adjustments for adverse disease
features, older adults routinely demonstrate outcomes significantly
inferior to those of younger adults.34,35 This underscores the need
to move to transplant expeditiously after initial treatment–induced
response as well as to explore posttransplant maintenance and
adoptive immunotherapy approaches following RIC or NMA allo-
geneic HCT in older adults.
In summary, the utilization of allogeneic HCT in adults aged
$70yearswith hematologicmalignancies hasmarkedly increasedover
the past decade. Nearly 40% of adults in this age group are alive at
2 years following transplant, suggesting that this approach is feasible,
offers promising disease control, and should be considered more
frequently for patients in their eighth decade with transplant-eligible
diseases.
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